Scarica l'app Stockscreener
22.59
0.22%
0.05
Precedente Chiudi:
$22.54
Aprire:
$22.59
Volume 24 ore:
1.51M
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.57B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-6.4313
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
-3.71%
1M Prestazione:
-50.89%
6M Prestazione:
+38.59%
1 anno Prestazione:
-64.51%
Intervallo 1D:
$22.23
$23.00
Intervallo di 1 settimana:
$21.20
$23.84
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
22.59 | 1.57B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-09-02 | Ripresa | William Blair | Outperform |
| 2026-07-30 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-06-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2026-06-17 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire
uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
UniQure Shares Fall After Barclays Downgrade - marketscreener.com
Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo
Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us
Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT
$uniQure NV (QURE.US)$ - Moomoo
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha
EBITDA of uniQure N.V. – HAN:UQ1 - TradingView
Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar
Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - The Transylvania Times
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression SlowingSlideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha
QURE Investor Alert: uniQure Securities InvestigationKehoe Law Firm, P.C. - GlobeNewswire Inc.
Why Is uniQure Stock Sinking on Tuesday? - benzinga.com
Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance
uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - finance.yahoo.com
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - finance.yahoo.com
uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - finance.yahoo.com
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - finance.yahoo.com
uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha
Why is uniQure stock collapsing today? - Investing.com
uniQure Announces Additional Data from Ongoing Phase I/II - globenewswire.com
UniQure’s gene therapy continues to slow Huntington’s progression after four years - STAT
UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com
uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions - Simply Wall Street
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Yahoo Finance
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure Nv Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | Officer |
Jul 02 '26 |
Proposed Sale |
45.15 |
21,082 |
951,932 |
0 |
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Proposed Sale |
46.42 |
30,000 |
1,392,643 |
0 |
| Kaye Jack | Director |
Jun 30 '26 |
Proposed Sale |
46.44 |
21,167 |
983,033 |
0 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 26 '26 |
Sale |
46.86 |
1,434 |
67,197 |
168,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 26 '26 |
Proposed Sale |
46.86 |
1,434 |
67,197 |
0 |
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):